FibroBiologics, a biotech company developing therapies for chronic diseases, has appointed Leigh Steinberg, a renowned sports agent and advocate for brain health and longevity, to its Board of Directors. Steinberg brings decades of experience in dealmaking and a strong commitment to chronic disease awareness, enhancing FibroBiologics' efforts in fibroblast-based treatments and human longevity programs. His expertise and network across sports, medicine, and business are expected to support the company's growth and innovation in therapeutic development.
Since 2022, the amount of credit card debt that is 90 days overdue has almost doubled, indicating growing financial stress among borrowers. However, the rate of new delinquencies has not increased, suggesting that while existing overdue balances are ...
Zoom Communications has been upgraded to a buy rating following recent underperformance that has eased valuation concerns. Despite modest 4.9% year-over-year revenue growth, Zoom shows operational strength with a strong cash position and a 24.6% GAAP...
Schall, Brown & Schwartz LLP announced a class action lawsuit against Replimune Group for allegedly making false and misleading statements about its Biologics License Application (BLA) to the FDA. The company reportedly submitted incomplete and unpla...
Replimune Group faces a class action lawsuit alleging violations of securities laws due to false and misleading statements about its FDA study design in its Biologics License Application. The lawsuit covers shareholders who bought Replimune shares be...
Nvidia's shares rose nearly 6% in premarket trading after the company reported earnings that exceeded expectations and provided strong revenue guidance. CEO Jensen Huang highlighted that AI demand has reached an inflection point, with a significant i...
